Risk of Alveolar Hemorrhage in Patients With Primary Pulmonary Hypertension-Anticoagulation and Epoprostenol Therapy-

• Ogawa Aiko

  Departments of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry

• Matsubara Hiromi

  Division of Cardiology, National Hospital Organization Okayama Medical Center

• Fujio Hideki

  Departments of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry

• Miyaji Katsumasa

  Departments of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry

• Nakamura Kazufumi

  Departments of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry

• Morita Hiroshi

  Departments of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry

• Saito Hironori

  Departments of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry

• Kusano Kengo Fukushima

  Departments of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry

• Emori Tetsuro

  Departments of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry

• Date Hiroshi

  Thoracic and Cancer Surgery, Okayama University Graduate School of Medicine and Dentistry

• Ohe Tohru

  Departments of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry

書誌事項

タイトル別名

• Anticoagulation and Epoprostenol Therapy

抄録

Background Anticoagulation therapy and continuous intravenous infusion of epoprostenol are the standard treatment for primary pulmonary hypertension (PPH). Because epoprostenol has an antiplatelet effect, concomitant use of an anticoagulant could increase the likelihood of hemorrhagic complications. Methods and Results In the present study, 31 consecutive patients with PPH (10 men, 21 women, mean ± SD age, 28.5±10.1 years) treated with anticoagulation and epoprostenol between April 1999 and December 2003 were retrospectively evaluated. Clinical and hematological data at the time of the bleeding episode were retrieved from the medical records. Nine patients (22.6%) experienced 11 bleeding episodes: 9 episodes (81.8%) were alveolar hemorrhage and 2 patients were in severe respiratory distress. The mean dose of epoprostenol at the time of the first bleeding episode was 89.0 ±40.5 ng · kg^-1 · min^-1 (range, 28.1-164.0). More of the patients who did not have a bleeding episode remain alive than did patients with bleeding episodes (59% vs 33%) nor did they require lung transplantation. Conclusions A considerable number of patients with PPH who received combined anticoagulant and high-dose epoprostenol therapy developed alveolar hemorrhage, which can be fatal. (Circ J 2005; 69: 216 - 220)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 69 (2), 216-220, 2005

  一般社団法人 日本循環器学会

キーワード

• Alveolar hemorrhage
• Anticoagulation
• Epoprostenol
• Primary pulmonary hypertension

詳細情報

• CRID: 1390282680079265536
• NII論文ID: 110002696074
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.69.216
• COI: 1:STN:280:DC%2BD2M%2FktlSmsA%3D%3D
• ISSN: 13474820
• ISSN: 13469843
• ISSN: http://id.crossref.org/issn/13469843
• PubMed: 15671616
• Web Site: http://www.jstage.jst.go.jp/article/circj/69/2/69_2_216/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2006247891
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可